• 1
    Warrell DA, Cox TM, Firth JD, Benz EJ, eds. Oxford Textbook of Medicine, Section 24: Neurology.Oxford: Oxford University Press; 2004.
  • 2
    Headache Classification Subcommittee of the International Headache Society. International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004;24:8-152.
  • 3
    Snow V, Weiss K, Wall EM, Mottur-Pilson C. American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137:840-849.
  • 4
    Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselblad V. Drug treatments for the prevention Of migraine. Technical review 2.3. February 1999. Prepared for the Agency for Health Care Policy and Research under Contract No. 290-94-2025.
  • 5
    Modi S, Lowder DM. Medications for migraine prophylaxis. Am Fam Physician. 2006;73:72-78
  • 6
    Olsson JE, Behring HC, Forssman B, et al. Metoprolol and Propanolol in migraine prophylaxis: A double-blind multicenter study. Acta Neurol Scand. 1984;70:160-168.
  • 7
    Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine: A double-blind study. Cephalalgia. 1984;4:91-96.
  • 8
    Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;22:491-512.
  • 9
    Schellenberg R. Migraine Prophylaxis: Possibilities and Practical Applications [Migräneprophylaxe – Möglichkeiten und praktische Anwendungen ]. UNI-MED Verlag AG: Bremen-London-Boston; 2001.
  • 10
    McNeely W, Goa KL. Nebivolol in the management of essential hypertension: A review. Drugs. 1999;57:633-651.
  • 11
    Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation betablocking agents in chronic heart failure. Clin Cardiol. 1998;21(suppl 1):I3-13.
  • 12
    Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
  • 13
    Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res. 1998;38:419-431.
  • 14
    Zanchetti A. Clinical pharmacodynamics of nebivolol: New evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl.2004;1:17-32.
  • 15
    Ritter JM. Nebivolol: Endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38:S13-S16.
  • 16
    Duprez D, Lefebvre R, De Backer T, De Sutter P, Trouerbach J, Clement DL. Influence of nebivolol on the cardiovascular hemodynamics during postural changes and isometric exercise. Cardiovasc Drugs Ther. 1991;5:709-717.
  • 17
    Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205.
  • 18
    Cockcroft J. Nebivolol: A review. Expert Opin Pharmacother. 2004;5:893-899.
  • 19
    Pessina AC. Metabolic effects and safety profile of nebivolol. J Cardiovasc Pharmacol. 2001;38:S33-S35.
  • 20
    Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the migraine disability assessment (MIDAS) score. Neurology. 1999;53:988-994.
  • 21
    National Institutes of Mental Health CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery. 2. Revised ed. In: GuyW, BonatoRR, eds. Chevy Chase, MD: National Institutes of Mental Health; 1970:12-1-12-6.
  • 22
    Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ. 1992;305:160-164.